Glenn Foundation Lures Scientists And Funders To Biology Of Aging

In just over a decade, genetically engineered mice have brought dramatic changes to the biomedical sciences, offering basic researchers ways to detect the influences of single genes and more clinically oriented investigators compellingly close models of human disease. Of Aging A small California foundation that does not accept grant applications has nonetheless gained ground as an unusually flexible seed funder and advocate for research in the biology of aging. Researchers and officials

Written byBrad Warren
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Of Aging A small California foundation that does not accept grant applications has nonetheless gained ground as an unusually flexible seed funder and advocate for research in the biology of aging. Researchers and officials in this field say the Glenn Foundation for Medical Research, endowed and run by venture capitalist Paul Glenn, is helping to crack the door on a broad area of biological investigation that still commands only a portion of the federal budget for medical research. Glenn "does fill some holes we can't handle," says Huber Warner, deputy associate director of the program on the biology of aging at the National Institute on Aging (NIA). That program had just $44 million for research grants in fiscal 1993, enough to fund only about 15 percent of proposals that cleared its peer-review process, he says. Glenn's Santa Barbara, Calif.-based philanthropy is one of a small cadre of private donors that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies